Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuxi AppTec CoWUXIF 82 EV-to-OCF is 23.58 as of Aug. 12, 2026, which is 46% below its 10-year median of 44.06. GuruFocus rates WUXIF with a GF Score™ of 82/100 and a GF Value™ of $12.85 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks worse than 77% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Wuxi AppTec Co's Enterprise Value is $66,110 Mil.
Wuxi AppTec Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $2,804 Mil. Therefore, Wuxi AppTec Co's EV-to-OCF for today is 23.58.
The historical rank and industry rank for Wuxi AppTec Co's EV-to-OCF or its related term are showing as below:
WUXIF'
s EV-to-OCF Range Over the Past 10 Years
Min: 7.99 Med: 44.06 Max: 127.51
Current: 22.91
During the past 12 years, the highest EV-to-OCF of Wuxi AppTec Co was 127.51. The lowest was 7.99. And the median was 44.06.
WUXIF's EV-to-OCF is ranked worse than 77% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.35
vs WUXIF: 22.91
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wuxi AppTec Co (OTCPK:WUXIF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wuxi AppTec Co's PE Ratio (TTM) for today is calculated as:
Wuxi AppTec Co's share price for today is $20.78.
Wuxi AppTec Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.063.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Wuxi AppTec Co EV-to-OCF Related Terms
Wuxi AppTec Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Wuxi AppTec Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's EV-to-OCF falls into.
Wuxi AppTec Co's current Enterprise Value is $66,110 Mil.
Wuxi AppTec Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,804 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co (WUXIF) has a EV-to-OCF of 23.58 as of Aug. 12, 2026. This is 46% below median its historical median of 44.06. Over the past decade, Wuxi AppTec Co's EV-to-OCF has ranged from 7.99 to 127.51. According to the industry distribution chart, Wuxi AppTec Co ranks #164 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 77%.
Is Wuxi AppTec Co's EV-to-OCF too high?
Wuxi AppTec Co's current EV-to-OCF of 23.58 is 46% below median its 10-year median of 44.06. Over the past 10 years, this metric has ranged from a low of 7.99 to a high of 127.51. The Medical Diagnostics & Research industry median EV-to-OCF is 6.35. Wuxi AppTec Co's value of 23.58 is 271.3% above this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #164 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Wuxi AppTec Co has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #164 out of 213 companies for EV-to-OCF. This places Wuxi AppTec Co in the lower half of its industry. The industry median EV-to-OCF is 6.35. Wuxi AppTec Co's value of 23.58 is 271.3% above this benchmark. Historically, Wuxi AppTec Co's own EV-to-OCF has ranged from 7.99 to 127.51 over the past decade. While the company's 10-year median is 44.06 vs. the industry median of 6.35, Wuxi AppTec Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.35, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current EV-to-OCF of 23.58 is 271.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current EV-to-OCF is 23.58, which is 46% below median its own 10-year median of 44.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.85, compared to a current price of $20.78 — trading 61.7% above its estimated fair value. The current EV-to-OCF is 23.58, which is 46% below median its 10-year median of 44.06 and 271.3% above the Medical Diagnostics & Research industry median of 6.35. Wuxi AppTec Co's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current EV-to-OCF is 23.58 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $20.78 is trading 61.7% above its estimated GF Value™ of $12.85.
GuruFocus considers Wuxi AppTec Co to be Modestly Overvalued.
Key valuation signals for WUXIF:
EV-to-OCF: 23.58 (46% below median its 10-year median of 44.06)
GF Value™: $12.85 vs. price of $20.78 (61.7% above fair value)
Industry Position: 271.3% above the Medical Diagnostics & Research median (#164 of 213)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
82GF Score
Get the complete analysis for WUXIF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
